Can This Patient Use Eliquis (Apixaban) for Anticoagulation?
Yes, apixaban can be used for this patient with a mural thrombus in the descending thoracic aorta, particularly if they have atrial fibrillation or venous thromboembolism, as apixaban is FDA-approved for both conditions and anticoagulation is the recommended first-line therapy for aortic mural thrombus. 1, 2, 3
Primary Indication Assessment
Determine the underlying indication for anticoagulation:
If atrial fibrillation is confirmed: Apixaban is FDA-approved and guideline-recommended for stroke prevention in nonvalvular AF 1, 4, 5
If venous thromboembolism is confirmed: Apixaban is FDA-approved for treatment of DVT/PE and prevention of recurrence 1, 7
Aortic Mural Thrombus Management
Anticoagulation is the recommended first-line therapy for descending thoracic aortic mural thrombus:
- Therapeutic anticoagulation is proposed as first-line therapy for mural thrombus in non-aneurysmal, non-atherosclerotic descending thoracic aorta 2, 8
- Multiple case series demonstrate successful thrombus resolution with anticoagulation therapy alone 2, 9, 10
- Surgical or endovascular intervention is reserved for: contraindication to anticoagulation, mobile thrombus, or recurrent embolism despite anticoagulation 2, 8
Important caveat: While historical literature primarily describes warfarin or heparin for aortic mural thrombus 2, 3, 8, apixaban is a reasonable alternative given its mechanism as a factor Xa inhibitor and proven efficacy in arterial and venous thrombosis 1
Contraindications to Exclude
Verify the patient does NOT have absolute contraindications to apixaban:
- Mechanical heart valves: Apixaban must not be used due to excessive thrombotic complications and increased major bleeding 6, 11
- Moderate-to-severe mitral stenosis: Warfarin with INR 2.0-3.0 is required instead 6, 11
- Severe renal impairment: CrCl <15 mL/min or dialysis is a contraindication 11, 5, 12
- Severe hepatic dysfunction: NOACs are not recommended 5
Dosing Strategy
Standard apixaban dosing of 5 mg twice daily, with dose reduction to 2.5 mg twice daily if the patient meets ≥2 of the following criteria: 6
- Age ≥80 years
- Weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Renal function monitoring is mandatory:
- Calculate creatinine clearance using Cockcroft-Gault equation before initiation 5, 6
- Recheck renal function at intervals based on degree of dysfunction and at least annually 5, 12
- Adjust dose according to FDA guidelines if renal function changes 5
Monitoring and Follow-Up
Assess for bleeding complications:
- Major bleeding criteria include: bleeding at critical site, hemodynamic instability, hemoglobin decrease ≥2 g/dL, or transfusion of ≥2 units 12
- For major bleeding: stop apixaban immediately, provide supportive care, consider reversal agents (prothrombin complex concentrates or andexanet alfa) for life-threatening bleeding 12
- Apixaban can be resumed at least 6 hours after hemostasis is achieved if anticoagulation remains indicated 12
Imaging surveillance for thrombus resolution:
- Repeat imaging (CT or transesophageal echocardiography) to document thrombus resolution or regression 2, 3, 10
- If thrombus persists or recurrent embolic events occur despite therapeutic anticoagulation, consider endovascular or surgical intervention 2, 3, 8
Common Pitfalls to Avoid
- Do not use apixaban if the patient has a mechanical valve or moderate-to-severe mitral stenosis - these are absolute contraindications requiring warfarin instead 6, 11
- Do not underdose - ensure proper dose reduction criteria are met (need ≥2 factors, not just 1) 6
- Do not ignore renal function - apixaban accumulates in renal failure and requires dose adjustment or alternative therapy 5, 12
- Do not assume bioprosthetic valves are a contraindication - apixaban is acceptable for bioprosthetic valves ≥3 months post-implantation 6, 5